My research involves using next-generation sequencing and functional proteomic approaches to identify targetable molecular alterations in solid tumours, and also those molecular alterations that contribute to cancer resistance to targeted therapies. My research also aims to determine if circulating DNA/CTCs can be used as a “liquid biopsy” in patients undergoing treatment, to monitor tumour biology and, in particular, changes in therapeutic targets over the course of time and treatment.